{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["46(41)"],"submitter":["Pareek M"],"funding":["Pfizer Inc."],"pubmed_abstract":["Background and aims
It is not known whether the bivalent respiratory syncytial virus prefusion F protein-based (RSVpreF) vaccine reduces outcomes in individuals with atherosclerotic cardiovascular disease (ASCVD). The aim was to evaluate the vaccine effectiveness (VE) of an RSVpreF vaccine vs no vaccine on respiratory and cardiovascular outcomes in persons with or without pre-existing ASCVD.Methods
We conducted a prespecified secondary analysis of the DAN-RSV trial. Adults aged ≥60 years were randomized 1:1 to RSVpreF vaccine or no vaccine. Baseline and outcome data were collected through nationwide registries. The primary outcome was respiratory syncytial virus-related respiratory tract disease hospitalization. The principal major adverse cardiovascular event outcome was a"],"journal":["European heart journal"],"pagination":["4291-4298"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12579979"],"repository":["biostudies-literature"],"pubmed_title":["Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial."],"pmcid":["PMC12579979"],"pubmed_authors":["Wiese L","Skaarup KG","Davidovski FS","Dons M","Schwarz C","Kober L","Aliabadi N","Lindholm MG","Larsen L","Dalager-Pedersen M","Begier E","Duus LS","Claggett BL","Jensen JUS","Nielsen AB","Zhang P","Jensen AMR","Skovdal M","Fussing FH","Larsen CS","Martel CJ","Christensen SH","Ottosen CI","Gessner BD","Kose G","Gonzalez E","Bernholm KF","Johansen ND","Pareek M","Lassen MCH","Modin D","Solomon SD","Biering-Sorensen T","Borchsenius JH","Espersen C"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial.","description":"Background and aims
It is not known whether the bivalent respiratory syncytial virus prefusion F protein-based (RSVpreF) vaccine reduces outcomes in individuals with atherosclerotic cardiovascular disease (ASCVD). The aim was to evaluate the vaccine effectiveness (VE) of an RSVpreF vaccine vs no vaccine on respiratory and cardiovascular outcomes in persons with or without pre-existing ASCVD.Methods
We conducted a prespecified secondary analysis of the DAN-RSV trial. Adults aged ≥60 years were randomized 1:1 to RSVpreF vaccine or no vaccine. Baseline and outcome data were collected through nationwide registries. The primary outcome was respiratory syncytial virus-related respiratory tract disease hospitalization. The principal major adverse cardiovascular event outcome was a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-05T10:23:29.343Z","creation":"2026-05-15T03:12:31.31Z"},"accession":"S-EPMC12579979","cross_references":{"pubmed":["40884439"],"doi":["10.1093/eurheartj/ehaf679"]}}